Novartis Presentations at the 2021 ASCO Annual Meeting
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Alpelisib
Long-term (LT) disease control in patients (pts) with hormone receptor–positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL)
Alpelisib
Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
Ribociclib
Updated overall survival (OS) results from the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
Ribociclib
Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC).
Patient Related Experience
Do you hear us? Elevating the voice of patients (pts) from Asia Pacific (AP) & Middle East (ME) in pharmaceutical research
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Capmatinib
Capmatinib in 𝘔𝘌𝘛 exon 14-mutated, advanced non-small cell lung cancer (NSCLC): updated results from the GEOMETRY mono-1 study
Capmatinib
Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety.
Capmatinib
Patient-reported outcomes in capmatinib-treated patients (pts) with METex14- mutated advanced non-small cell lung cancer (NSCLC): results from the Phase II GEOMETRY mono-1 study
Capmatinib
Capmatinib efficacy in patients with NSCLC identified as METex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study.
Tislelizumab
The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen. This trial has been sponsored and conducted by BeiGene.
Tislelizumab
RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65. This trial has been sponsored and conducted by BeiGene.
Disease Specific
Novel elements of value in the context of oncology
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Dabrafenib + Trametinib
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib plus trametinib (dab + tram): Primary results of COMBI-APlus.
Spartalizumab
Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DAB + TRAM) in the COMBI-i trial
Real-world Evidence
Comprehensive real-world evidence in stage III and IV melanoma – evaluation of a cohort of patients (pts) treated at a Portuguese institution
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
177Lu-DOTATATE
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.
177Lu-DOTATATE
Efficacy and safety of 177Lu-DOTATATE in patients (pts) with pancreatic neuroendocrine tumors (pNETs): data from the NETTER-R international, retrospective registry
Pasireotide
First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus (EVE) in patients (pts) with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
177Lu-PSMA-617
Phase III study of lutetium-177-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (VISION)
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Advanced Solid Tumors
Advanced Solid Tumors
NIS793
Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors
TNO155
A dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Tislelizumab
RATIONALE 302: Randomized, Phase III study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma. This trial has been sponsored and conducted by BeiGene.
Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NIS793
Phase II study of the anti-TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)
Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors
Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors
Tislelizumab
A Phase II study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors. This trial has been sponsored and conducted by BeiGene.
PIK3CA-related Overgrowth Spectrum (PROS)
PIK3CA-related Overgrowth Spectrum (PROS)
Alpelisib
EPIK-P2: A prospective Phase II, double-blind, randomized, placebo-controlled study of alpelisib (ALP) in pediatric and adult patients (Pts) with PIK3CA-related overgrowth spectrum (PROS)
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Tisagenlecleucel
Comparison of efficacy outcomes between tisagenlecleucel (TISA-CEL) and lisocabtagene maraleucel (LISO-CEL) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)
Tisagenlecleucel
Safety and efficacy of tisagenlecleucel (TISA-CEL) plus pembrolizumab (PEMBRO) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): updated Analysis of the Phase Ib PORTIA Study
Tisagenlecleucel
Health care resource use (HRU) by Chimeric antigen receptor T-cell (CAR-T) infusion setting among patients (pts) with relapsed and refractory (r/r) DLBCL – a retrospective cohort study using CMS 100% Medicare database
Tisagenlecleucel
Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients (pts) with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (TISA-CEL) and axicabtagene ciloleucel (AXI-CEL): a summary of real-world evidence
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Tisagenlecleucel
Efficacy and safety of tisagenlecleucel (TISA-CEL) in adult patients (pts) with relapsed/refractory follicular lymphoma (r/r FL): primary analysis of the Phase II ELARA Trial
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Sabatolimab
Treatments and outcomes for patients (pts) with myelodysplastic syndrome (MDS) by revised international prognostic scoring system (IPSS-R) scores at the Huntsman Cancer Institute (HCI)
